When should inhibin testing be ordered and how are the results interpreted for evaluating ovarian tumors and ovarian reserve?

Inhibin Testing in Clinical Practice

Inhibin testing should be ordered primarily for suspected granulosa cell tumors of the ovary and can be useful for mucinous epithelial ovarian cancers in postmenopausal women, but it has no established role in evaluating ovarian reserve for fertility purposes.

When to Order Inhibin Testing for Ovarian Tumors

Primary Indications

Granulosa cell tumors are the clearest indication for inhibin testing. Inhibin is secreted by granulosa cell tumors and serves as a useful marker for this disease 1. The evidence is strongest in postmenopausal women, where:

• Sensitivity: 100% for granulosa cell tumors (all 3 cases detected) 2
• Specificity: High when combined with clinical context
• Inhibin levels correlate with disease presence and tumor burden 3

Secondary Indications

Mucinous epithelial ovarian cancers show elevated inhibin in a substantial proportion of cases:

• 82% of mucinous carcinomas have elevated serum inhibin 2
• When combined with CA-125, detection of epithelial ovarian cancers reaches 99% sensitivity at 95% specificity 4
• Total inhibin detected 94% of mucinous tumors at 95% specificity 4

Limited Utility in Other Tumor Types

Inhibin has poor sensitivity for:

• Serous carcinomas: only 17% positive 2
• Clear-cell carcinomas: 17% positive 2
• Undifferentiated carcinomas: 15% positive 2

Clinical Algorithm for Ordering Inhibin

Order inhibin testing when:

1. Postmenopausal woman with pelvic mass and clinical features suggesting sex cord-stromal tumor:

   • Abnormal vaginal bleeding
   • Endometrial hyperplasia
   • Estrogenic symptoms
   • Age typically 50+ years for adult-type granulosa cell tumors 1

2. Young woman (<40 years) with:

   • Virilization symptoms (suggesting Sertoli-Leydig cell tumor)
   • Precocious puberty in prepubertal girls (juvenile granulosa cell tumor) 1

3. Known mucinous ovarian tumor in postmenopausal women for enhanced diagnostic accuracy 4, 2

4. Combination testing approach: Order inhibin alongside CA-125, AFP, beta-hCG, and LDH as part of comprehensive tumor marker panel for non-epithelial ovarian tumors 1, 5

Interpreting Inhibin Results

Diagnostic Thresholds

• Cut-off for malignancy: >1.155 U/mL (95th percentile of normal controls) provides:

  • 100% specificity for malignancy
  • 67.7% sensitivity 6

• For granulosa cell tumor recurrence: >7 pg/mL (inhibin B) shows:

  • 98.8% sensitivity (95% CI: 95.8-99.9%)
  • 88.9% specificity (95% CI: 82.6-93.5%) 3

Result Interpretation by Clinical Context

Elevated inhibin in postmenopausal women indicates:

• High probability of granulosa cell tumor (if very elevated)
• Possible mucinous carcinoma (moderate elevation)
• Less likely: other epithelial ovarian cancers or benign disease

Post-surgical monitoring:

• Inhibin levels should fall significantly within one week after complete tumor removal 2
• Persistent elevation suggests residual disease
• Rising levels during follow-up indicate recurrence 3

Correlation with Tumor Burden

Inhibin B levels correlate positively with lesion size in granulosa cell tumors 3:

• 15.6 pg/mL = 25% probability of abnormal CT
• 44.6 pg/mL = 50% probability of abnormal CT
• 73.6 pg/mL = 75% probability of abnormal CT

This relationship can guide timing of imaging studies during surveillance.

Follow-Up Monitoring

For granulosa cell tumors, long-term inhibin monitoring is essential 7:

• Measure inhibin B (or total inhibin, estradiol, LH, FSH) every 6 months indefinitely starting from year 3 8
• Recurrences can occur up to 20-37 years after initial diagnosis 7, 8
• More useful in postmenopausal or castrated patients 7
• Anti-Müllerian hormone (AMH) is emerging as a potential replacement marker 7

Inhibin Testing Has NO Role in Ovarian Reserve Assessment

Critical distinction: Despite inhibin being an ovarian hormone, inhibin B is NOT recommended for clinical assessment of ovarian reserve 9, 10:

• Poor predictor of reproductive potential independent of age 9
• Not among relevant markers for ovarian reserve evaluation 10
• Preferred markers for ovarian reserve: Anti-Müllerian hormone (AMH), antral follicle count (AFC), FSH with estradiol 11, 9, 10

The ACR Appropriateness Criteria for female infertility evaluation does not include inhibin testing 12, and fertility preservation guidelines focus on AMH rather than inhibin 11, 13.

Common Pitfalls to Avoid

1. Don't use inhibin for ovarian reserve testing - this is a common misconception given inhibin's ovarian origin
2. Don't rely on inhibin alone for epithelial ovarian cancer diagnosis - always combine with CA-125 4, 14
3. Don't order in premenopausal women with suspected epithelial cancers - specificity is reduced
4. Don't assume negative inhibin rules out ovarian cancer - most serous carcinomas are inhibin-negative 2
5. Don't forget long-term monitoring for granulosa cell tumors - late recurrences are characteristic 7, 8